Floatz logo

Pralsetinib, trans-

Respiratory Tract Disease

Hoffmann-La RocheSmall moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Respiratory Tract Disease cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 3BB
NEOSTIGMINE
Coastal Anesthesiology Consultants
Phase 4BB
Rocuronium
Ziekenhuis Oost-Limburg
Phase 4BB
NEOSTIGMINE
Ziekenhuis Oost-Limburg
Phase 4BB
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Ziekenhuis Oost-Limburg
Phase 4BB

View all 33 →

Same molecule, other indications

Pralsetinib, trans- is also rated in:

neoplasmDormant
BB
Indicative ·
67 / 100
View asset →
germ cell tumorDormant
BB
Indicative ·
66 / 100
View asset →
lung neoplasmDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →